Skip to main content

Nasdaq Technology

Anthropic Starts Marketing Shares Ahead of IPO

1 week 1 day ago
Claude developer Anthropic has started marketing its shares to investors ahead of a Nasdaq listing that would rank as the second largest initial public offering (IPO) on record.The company said on Tuesday (November 10) that it plans to sell 825 million Class A shares at US$70 to US$78 each. Anthropic is offering about 801.4 million of those shares, and existing stockholders are selling the remaining 23.6 million. Anthropic expects to give underwriters a 30 day option to buy up to 123.75 million more.At the top of the range, the base offering would raise about US$64.4 billion. CBC News reported that the range implies a fully diluted valuation of roughly US$1.3 trillion at the midpoint and US$1.4 trillion at the top end.Citing people familiar with the matter, Bloomberg reported on Wednesday (November 11) that the deal has drawn orders for multiple times the shares on offer. CNBC said that Anthropic aims to start trading on November 19. The company has applied to list on the Nasdaq Global Select Market under the ticker “ANT,” with Goldman Sachs (NYSE:GS) and Morgan Stanley (NYSE:MS) leading the offering.Seven companies, including NVIDIA (NASDAQ:NVDA), Google and Microsoft (NASDAQ:MSFT), plan to buy another US$26 billion of stock in a concurrent private placement, according to IPO research firm Renaissance Capital.Until now, public investors seeking AI exposure have largely relied on companies such as Microsoft and NVIDIA, which run large businesses beyond AI models.Anthropic’s revenue reached US$17 billion in the third quarter, up from US$11.6 billion in the second quarter and US$1.4 billion a year earlier, according to an amended filing reported by Fortune. But the company swung to a US$567 million operating loss from a US$974 million operating profit in the prior quarter, which it blamed mainly on higher-cost compute bought under short-term contracts.The prospectus devotes 94 of its more than 300 pages to risk factors, including a warning that the company’s models could take actions that “pose catastrophic or existential risks to humanity.”At US$64.4 billion, the offering would trail only Space Exploration Technologies' (NASDAQ:SPCX) June listing, which raised US$75 billion. SpaceX shares have since traded as much as 22 percent below their US$135 IPO price.Founded in 2021 by former OpenAI staff, Anthropic is organized as a public benefit corporation, which requires its board to balance public safety against shareholder returns.Don’t forget to follow us @INN_Technology for real-time news updates!Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

5 Best-performing Canadian Pharma Stocks in 2026

1 week 1 day ago
From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic.Canadian drug companies are working to discover, develop and commercialize major innovations amid an increasingly competitive global landscape. Rising technologies such as artificial intelligence are playing a role in the sector as well.Here, the Investing News Network lists the top Canadian pharma stocks on the TSX, TSXV and CSE by year-to-date gains. All data was compiled on November 7, 2026, using TradingView’s stock screener.Read on to learn about what's been driving the share prices of the best-performing Canadian pharma stocks. 1. BetterLife Pharma (CSE:BETR) Year-to-date gain: 411.11 percentMarket cap: C$139.05 millionShare price: C$0.23BetterLife Pharma is developing drugs that aim to treat severe headache disorders by helping the brain form and strengthen connections between nerve cells. It relies on outside partners for manufacturing and lab testing rather than doing this work in-house.Its lead drug candidate, BETR-001, is a modified version of LSD designed not to cause hallucinations. In July, BetterLife narrowed its focus to migraines and other headache disorders. Part of its reasoning was that the US Food and Drug Administration (FDA) has already approved other headache drugs that work on serotonin receptors, the same brain target. The drug has not yet been tested in people.To lead that work, BetterLife named Doug Drysdale executive chairman in May. Drysdale is the former CEO of Cybin, now Helus Pharma (NASDAQ:HELP), with which he successfully guided a psychedelic molecule from its initial lab design to Phase 3 human clinical trials in just three years. Over the summer, BetterLife hired partners to manufacture the drug and run its final safety study in animals. Both steps are needed before it can apply to the FDA to begin human trials.In September, BetterLife closed a US$100 million share sale led by Deep Track Capital. The company plans to use the money for early safety trials in healthy volunteers and then trials in patients with cluster headache and migraine. In October, it set up a scientific advisory board for the headache program as it prepares its FDA application. 2. Medicure (TSXV:MPH) Year-to-date gain: 250.88 percentMarket cap: C$43 millionShare price: C$4.00Medicure is a Canadian drug company based in Winnipeg, Manitoba, that sells two prescription drugs in the US. Aggrastat is a heart drug given to prevent blood clots during and after heart attacks and heart procedures. Zypitamag is a cholesterol-lowering pill. Medicure also owns a group of US pharmacies, including the mail-order pharmacy Marley Drug, which now brings in most of its revenue.In its Q2 results, quarterly revenue rose to C$7.4 million compared to C$6.7 million in Q2 2025, driven by its pharmacies and Zypitamag. On the other hand, Aggrastat revenue fell sharply due to lower sales and price competition from a generic. In September, Medicure finished enrolling patients in its Phase 3 trial of MC-1 to treat PNPO deficiency, a very rare inherited disorder that causes severe seizures in newborns. The FDA has granted MC-1 fast track designation. 3. Eastwood Bio-Medical (TSXV:EBM) Year-to-date gain: 100 percentMarket cap: C$132.95 millionShare price: C$1.90Eastwood Bio-Medical Canada is based in Richmond, British Columbia, Canada. It develops and sells natural health products under its Eleotin brand in Canada, the US and Asia. Its products are made from herbal ingredients and are marketed for blood sugar, blood pressure, weight, digestion, sleep and heart health.In July, Eastwood signed a research agreement with BioNexus, a South Korean bio-data company. The partners will use artificial intelligence to analyze herbal prescription records gathered by Eastwood and its affiliates, which the company says have mostly never been digitized. The first step is a test study on about 250,000 prescriptions related to blood-glucose health. The two companies will jointly own the resulting data. 4. Knight Therapeutics (TSX:GUD) Year-to-date gain: 86.78 percentMarket cap: C$1.11 billionShare price: C$11.30Knight Therapeutics is a drug company based in Montreal, Québec, that buys or licenses the rights to existing drugs and sells them in Canada and Latin America. Its Latin American businesses include United Medical, Biotoscana Farma and Laboratorio LKM.In its Q2 results, Knight reported revenue of C$144.21 million, up 34 percent from a year earlier, and raised its full-year revenue forecast to between C$540 million and C$560 million. During the quarter, it launched several drugs in Latin America, including the blood disorder drug Tavalisse in Mexico. It also has approval to launch Tavalisse in Brazil in the second half of 2026. Knight paid off the loan it took out to buy Paladin, a Canadian drug business, in 2025. 5. Medexus Pharmaceuticals (TSX:MDP) Year-to-date gain: 74.39 percentMarket cap: C$156.19 millionShare price: C$5.04Medexus Pharmaceuticals is a specialty drug company that acquires, develops and sells drugs for niche and rare diseases in North America. It focuses on blood disorders, cancer, rheumatology, autoimmune disease, allergies and dermatology. Its strategy is to license drugs that are late in development or already on the market, then handle approval and sales in Canada and the US.Grafapex, which launched in the US in February 2025, is one of the most important branded products in the company’s portfolio. It’s used with another drug, fludarabine, to prepare patients with acute myeloid leukemia and myelodysplastic syndromes for a stem cell transplant from a donor.In June, Medexus secured the Canadian rights to UM171, a cell therapy already conditionally approved in the European Union. Medexus doesn’t expect to begin selling it before 2028. This deal adds a longer-term pipeline angle beyond Medexus' core commercial business.According to its fiscal Q1 2027 results for the three months ended June 30, revenue rose 16.3 percent year-over-year to US$28.6 million, and Grafapex had its best quarter since launch at US$3.2 million. The company expects Grafapex to bring in US$30 million to US$32 million this fiscal year, and between US$100 million and US$175 million a year within five years of launch. Don’t forget to follow us @INN_LifeScience for real-time news updates!Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

What Questerre Energy (QEC) Said on Its Q3 Earnings Call

1 week 1 day ago
Questerre Energy (TSE:QEC) reported positive adjusted funds flow of CAD 2.3 million in the third quarter despite an emergency turnaround at its Brazilian oil shale plant, while executives said they had begun discussions to restructure secured debt ahead of higher maintenance spen
Checked
33 minutes 1 second ago
This feed is responsible for generating the rss feed related to the topic Technology
Subscribe to Nasdaq Technology feed